Curative Biotechnology Inc (CUBT) Key Metrics
CUBT valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $8.1M
- Enterprise value
- $8.9M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 158.5
- Price / book
- —
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.30
CUBT key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsCUBT returns How much profit the business earns on the capital it uses.
Return on assets+43.6 pts
−105.9%
2025 · hover or tap a bar for each year
20162025
Asset turnover
0.00
2025 · hover or tap a bar for each year
20162025
CUBT financial health Debt, liquidity and how easily interest is covered.
Net debt−$36,510
$1.3M
2025 · hover or tap a bar for each year
20162025
Current ratio−55.2%
0.01
2025 · hover or tap a bar for each year
20162025
Interest coverage
-1.5
2025 · hover or tap a bar for each year
20162025
Debt / assets+1.7%
0.64
2025 · hover or tap a bar for each year
20162025
CUBT valuation history
Fiscal year-endToday10-year median
CUBT returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
CUBT debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
CUBT price vs earnings per share
Share price at year-endEPS (right axis)
CUBT key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | — | $11.6M | $14.1M | $11.4M | $17.4M | — | $742,441 | $32,280 | $32,280 | $64,560 |
| Enterprise value | — | $13.0M | $16.3M | $12.5M | $16.8M | — | $742,565 | $231,047 | $230,897 | $263,027 |
| P/E ratio | — | — | — | — | — | — | 2.2 | — | — | — |
| Price / sales | — | — | — | — | — | — | — | — | — | 5.8 |
| Price / book | — | — | — | — | 10.4 | — | — | — | — | — |
| EV / sales | — | — | — | — | — | — | — | — | — | 23.7 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | 69.2 |
| Earnings yield | — | −30.7% | −28.1% | −47.0% | −30.6% | — | 44.7% | −92.7% | −71.2% | −27.0% |
| Free cash flow yield | — | −8.8% | −3.5% | −14.1% | −9.3% | — | −0.0% | −0.5% | −0.5% | −9.1% |
| Share price at fiscal year-end | $0.81 | $1.92 | $3.19 | $3.00 | $8.10 | $4.53 | $0.34 | $0.01 | $0.01 | $0.03 |
| Per share | ||||||||||
| Revenue per share | — | $0.00 | $0.00 | $0.00 | $0.00 | — | $0.00 | $0.00 | $0.00 | $0.01 |
| Earnings per share | — | −$0.59 | −$0.90 | −$1.41 | −$2.48 | — | $0.15 | −$0.01 | −$0.01 | −$0.01 |
| Operating cash flow per share | — | −$0.17 | −$0.11 | −$0.40 | −$0.75 | — | −$0.00 | −$0.00 | −$0.00 | −$0.00 |
| Free cash flow per share | — | −$0.17 | −$0.11 | −$0.42 | −$0.76 | — | −$0.00 | −$0.00 | −$0.00 | −$0.00 |
| Cash per share | — | $0.00 | $0.01 | $0.02 | $0.31 | — | — | — | — | — |
| Book value per share | — | −$0.81 | −$0.71 | −$0.67 | $0.78 | — | −$0.17 | −$0.32 | −$0.31 | −$0.30 |
| Tangible book value per share | — | −$1.03 | −$1.03 | −$1.09 | $0.06 | — | −$0.18 | −$0.32 | −$0.31 | −$0.30 |
| Capex per share | — | $0.00 | $0.00 | $0.02 | $0.01 | — | $0.00 | $0.00 | $0.00 | $0.00 |
| Debt per share | — | $0.23 | $0.51 | $0.28 | — | — | $0.00 | $0.09 | $0.09 | $0.09 |
| Shares outstanding | — | 6.1M | 4.4M | 3.8M | 2.2M | — | 2.2M | 2.2M | 2.2M | 2.2M |
| Change in shares outstanding | — | +37.1% | +15.8% | +77.2% | — | — | 0.0% | 0.0% | 0.0% | +0.0% |
| Returns & profitability | ||||||||||
| Return on assets (ROA) | −105.9% | −149.6% | −168.7% | −239.0% | −227.9% | −403.7% | 782.4% | −57.5% | −36.8% | −26.0% |
| Return on tangible assets | −282.2% | −437.5% | −335.1% | — | −625.6% | −218.9% | — | −66.4% | −45.6% | −30.4% |
| Free cash flow margin | — | — | — | — | — | — | — | — | — | −53.1% |
| Income quality (OCF / net income) | — | — | — | — | — | — | −0.00 | — | — | — |
| Financial health | ||||||||||
| Total debt | $1.4M | $1.4M | $2.3M | $1.1M | — | $559,761 | $125 | $198,767 | $198,617 | $198,467 |
| Cash & short-term investments | $45,043 | $19,534 | $56,400 | $58,668 | $670,263 | $160,607 | — | — | — | — |
| Net debt | $1.3M | $1.3M | $2.2M | $1.0M | −$670,263 | $399,154 | $125 | $198,767 | $198,617 | $198,467 |
| Debt / assets | 0.64 | 0.63 | 0.87 | 0.51 | — | 0.25 | 0.00 | 4.41 | 3.37 | 3.01 |
| Net debt / EBITDA | — | — | — | — | — | — | — | — | — | 52.23 |
| Current ratio | 0.01 | 0.03 | 0.11 | 0.01 | 1.03 | 3.21 | 0.00 | 0.00 | 0.01 | 0.01 |
| Quick ratio | 0.01 | 0.03 | 0.13 | 0.01 | 1.03 | 3.21 | 0.00 | 0.00 | 0.01 | 0.01 |
| Interest coverage | -1.5 | -2.2 | -1.4 | -4.9 | -28.4 | -134.3 | -0.3 | -0.3 | -0.4 | -0.1 |
| Working capital | −$8.1M | −$6.9M | −$5.1M | −$4.5M | $23,570 | $1.5M | −$397,103 | −$734,357 | −$709,744 | −$692,062 |
| Invested capital | −$4.8M | −$3.6M | −$940,644 | −$1.5M | $1.0M | −$4.1M | −$357,203 | −$490,514 | −$460,750 | −$437,917 |
| Tangible asset value | −$7.4M | −$6.3M | −$4.6M | −$22.2M | −$17.9M | −$4.7M | −$394,236 | −$689,281 | −$667,948 | −$644,965 |
| Net current asset value | −$8.1M | −$6.9M | −$5.1M | −$22.6M | −$18.0M | −$4.7M | −$397,103 | −$734,357 | −$709,744 | −$692,062 |
| Graham net-net per share | — | −$1.17 | −$1.28 | −$5.92 | −$8.40 | — | −$0.18 | −$0.34 | −$0.33 | −$0.32 |
| Capital allocation | ||||||||||
| Capex / revenue | — | — | — | — | — | — | — | — | — | 0.0% |
| Capex / depreciation | 0.00 | 0.00 | 0.14 | 0.77 | 3.16 | 6.47 | 1.29 | 0.00 | 0.00 | 0.00 |
| SG&A / revenue | — | — | — | — | — | — | — | — | — | 62.1% |
| Efficiency | ||||||||||
| Days sales outstanding | — | — | — | — | — | — | — | — | — | 143.8 |
| Days of inventory on hand | — | — | -432.8 | — | — | — | — | — | — | 1,479.7 |
| Days payables outstanding | — | 15,069.0 | 12,953.0 | 95,450.7 | 22,318.2 | 17,039.3 | 32,110.3 | 36,331.2 | 35,237.6 | 445,282.1 |
| Cash conversion cycle (days) | — | — | — | — | — | — | — | — | — | -443,658.5 |
| Receivables turnover | — | — | 0.00 | — | 0.00 | 0.00 | — | 0.00 | 0.00 | 2.54 |
| Payables turnover | — | 0.02 | 0.03 | 0.00 | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | 0.00 |
| Inventory turnover | — | — | — | — | — | — | — | — | — | 0.25 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.17 |
| Average receivables | — | — | $115,625 | — | $47,500 | $35,000 | $0 | $4,290 | $8,581 | $4,370 |
| Average payables | — | $3.8M | $3.5M | $2.1M | $412,367 | $247,466 | $466,346 | $527,648 | $511,766 | $496,520 |
| Average inventory | — | — | −$115,625 | — | — | — | $0 | $0 | $825 | $1,650 |
| Intangibles / total assets | 62.0% | 62.3% | 54.6% | 77.7% | 64.6% | 6.2% | 92.8% | 0.0% | 14.6% | 13.0% |
Computed from CUBT's annual financial statements (latest annual report filed December 31, 2025) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
CUBT valuation and financial ratios
It ended the year with $1.4 million of debt and $0.0 million in cash and short-term investments, net debt of $1.3 million.
See the CUBT income statement, the CUBT chart for price history, or the CUBT stock overview for the latest quote and news.
CUBT key metrics FAQ
How much debt does Curative Biotechnology have?
Curative Biotechnology had total debt of $1.4 million at the end of fiscal 2025.
What is Curative Biotechnology's current ratio?
Curative Biotechnology's current ratio was 0.01 at the end of fiscal 2025: current assets were 0.01 times current liabilities.